mutLBSgeneDB |
Gene summary for GPSM2 |
![]() |
Basic gene Info. | Gene symbol | GPSM2 |
Gene name | G-protein signaling modulator 2 | |
Synonyms | CMCS|DFNB82|LGN|PINS | |
Cytomap | UCSC genome browser: 1p13.3 | |
Type of gene | protein-coding | |
RefGenes | NM_013296.4, | |
Description | G-protein signalling modulator 2 (AGS3-like, C. elegans)G-protein-signaling modulator 2mosaic protein LGN | |
Modification date | 20141207 | |
dbXrefs | MIM : 609245 | |
HGNC : HGNC | ||
Ensembl : ENSG00000121957 | ||
HPRD : 06609 | ||
Protein | UniProt: P81274 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_GPSM2 | |
BioGPS: 29899 | ||
Pathway | NCI Pathway Interaction Database: GPSM2 | |
KEGG: GPSM2 | ||
REACTOME: GPSM2 | ||
Pathway Commons: GPSM2 | ||
Context | iHOP: GPSM2 | |
ligand binding site mutation search in PubMed: GPSM2 | ||
UCL Cancer Institute: GPSM2 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for GPSM2 |
![]() We represented ligand binding site mutations only. (You can see big image via clicking.) ![]() |
![]() |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | A28 | A28S | BLCA | 1 | R323 | A324T | BRCA | 1 | F73 | F73L | COAD | 1 | N147 | L148I | COAD | 1 | N247 | L248F | LUAD | 1 | D57 | E56K | LUSC | 1 | Q283 | E281D | STAD | 1 | E32 | R33C | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for GPSM2 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | N147 | L148I | -1.0160066 | N247 | L248F | -0.95066489 | A28 | A28S | -0.91520997 | E32 | R33C | -0.89085135 | R323 | A324T | -0.44726427 | D57 | E56K | -0.23611784 | F73 | F73L | -0.23059602 | Q283 | E281D | -0.10799956 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for GPSM2 |
![]() |
![]() |
Top |
Top |
Phenotype information for GPSM2 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
umls:C1858695 | Chudley-Mccullough syndrome | 2 | Biomarker, GeneticVariation |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for GPSM2 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of GPSM2 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |